TDC
CSBR icon

Thompson Davis & Co’s Champions Oncology CSBR Stock Holding History

Thompson Davis & Co’s Portfolio CSBR Stock Details CSBR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$9K Buy
+500
New +$4.45K 0.02% 467

Other funds holding CSBR

BPI
Battery Partners IX Boston, Massachusetts $22.4M AUM 27.71% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.63B AUM 38.09% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Thompson Davis & Co's CSBR Position: Q3 2018 in Review

Thompson Davis & Co opened a new position in Champions Oncology (CSBR) in Q3 2018: 500 shares worth $9K. The stake represents 0.02% of the portfolio and ranks #467 among its holdings.

37 funds tracked by Wall St. Rank hold CSBR as of Q3 2018.

  • Thompson Davis & Co held 500 shares of Champions Oncology worth $9K as of Q3 2018.
  • Champions Oncology was a new Thompson Davis & Co position in Q3 2018.
  • Champions Oncology made up 0.02% of Thompson Davis & Co's portfolio in Q3 2018, its #467 holding.
  • 37 funds tracked by Wall St. Rank held Champions Oncology as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.